Search research articles
Contact Us
Filters
Showing results (81-90 of 94) with videos related to
Page
of 10
Sort By:
The Australian & New Zealand Journal of Obstetrics & Gynaecology
|
February 1, 2024
Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand
Niveditha Rajadevan, Ariane Flinkier, Hugo Saunders, et al.
Academic Medicine : Journal of the Association of American Medical Colleges
|
January 26, 2024
Precision Education: The Future of Lifelong Learning in Medicine
Sanjay V Desai, Jesse Burk-Rafel, Kimberly D Lomis, et al.
Journal of Medicinal Chemistry
|
June 25, 2011
Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors
Jailall Ramnauth, Joanne Speed, Shawn P Maddaford, et al.
Journal for Immunotherapy of Cancer
|
June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Yoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
Cancers
|
January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)
Deborah Smith, Kristy P Robledo, Sonia Yip, et al.
Gynecologic Oncology
|
May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Cancer Immunology Research
|
May 7, 2015
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Ross Stewart, Michelle Morrow, Scott A Hammond, et al.
Mabs
|
January 5, 2021
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
Darren J Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, et al.
BMJ Open
|
April 13, 2023
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial
Sandra Hayes, Andreas Obermair, Linda Mileshkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2017
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Rebecca Leyland, Amanda Watkins, Kathy A Mulgrew, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 94) with videos related to
Sort By:
Page
of 10
The Australian & New Zealand Journal of Obstetrics & Gynaecology
|
February 1, 2024
Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand
Niveditha Rajadevan, Ariane Flinkier, Hugo Saunders, et al.
Academic Medicine : Journal of the Association of American Medical Colleges
|
January 26, 2024
Precision Education: The Future of Lifelong Learning in Medicine
Sanjay V Desai, Jesse Burk-Rafel, Kimberly D Lomis, et al.
Journal of Medicinal Chemistry
|
June 25, 2011
Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors
Jailall Ramnauth, Joanne Speed, Shawn P Maddaford, et al.
Journal for Immunotherapy of Cancer
|
June 9, 2021
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Yoland Antill, Peey-Sei Kok, Kristy Robledo, et al.
Cancers
|
January 8, 2023
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)
Deborah Smith, Kristy P Robledo, Sonia Yip, et al.
Gynecologic Oncology
|
May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Cancer Immunology Research
|
May 7, 2015
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Ross Stewart, Michelle Morrow, Scott A Hammond, et al.
Mabs
|
January 5, 2021
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
Darren J Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, et al.
BMJ Open
|
April 13, 2023
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial
Sandra Hayes, Andreas Obermair, Linda Mileshkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2017
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Rebecca Leyland, Amanda Watkins, Kathy A Mulgrew, et al.
Page
of 10